MX9302985A - Composicion farmaceutica para el tratamiento y la profilaxis de la ansiedad. - Google Patents

Composicion farmaceutica para el tratamiento y la profilaxis de la ansiedad.

Info

Publication number
MX9302985A
MX9302985A MX9302985A MX9302985A MX9302985A MX 9302985 A MX9302985 A MX 9302985A MX 9302985 A MX9302985 A MX 9302985A MX 9302985 A MX9302985 A MX 9302985A MX 9302985 A MX9302985 A MX 9302985A
Authority
MX
Mexico
Prior art keywords
prophylaxis
treatment
anxiety
pharmaceutical composition
mammals
Prior art date
Application number
MX9302985A
Other languages
English (en)
Inventor
Gordon Smith Baxter Gu Kennett
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211082A external-priority patent/GB9211082D0/en
Priority claimed from GB929214399A external-priority patent/GB9214399D0/en
Priority claimed from GB929219356A external-priority patent/GB9219356D0/en
Priority claimed from GB929227045A external-priority patent/GB9227045D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MX9302985A publication Critical patent/MX9302985A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe un método para el tratamiento y/o la profilaxis de la ansiedad en mamíferos, inclusive humanos, el método comprende administrar al mamífero en necesidad de tal tratamiento y/o profilaxis, una cantidad efectiva y/o profiláctica de un antagonista del receptor de 5-HT4.
MX9302985A 1992-05-23 1993-05-21 Composicion farmaceutica para el tratamiento y la profilaxis de la ansiedad. MX9302985A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929211082A GB9211082D0 (en) 1992-05-23 1992-05-23 Pharmaceuticals
GB929214399A GB9214399D0 (en) 1992-07-07 1992-07-07 Pharmaceuticals
GB929219356A GB9219356D0 (en) 1992-09-12 1992-09-12 Pharmaceuticals
GB929227045A GB9227045D0 (en) 1992-12-29 1992-12-29 Pharmaceuticals

Publications (1)

Publication Number Publication Date
MX9302985A true MX9302985A (es) 1993-11-01

Family

ID=27450876

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9302985A MX9302985A (es) 1992-05-23 1993-05-21 Composicion farmaceutica para el tratamiento y la profilaxis de la ansiedad.

Country Status (6)

Country Link
US (1) US5763459A (es)
EP (1) EP0641198A1 (es)
JP (1) JPH07507290A (es)
AU (1) AU4081393A (es)
MX (1) MX9302985A (es)
WO (1) WO1993024117A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
US5726187A (en) * 1992-10-16 1998-03-10 Smithkline Beecham Plc N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-HT4 receptor antagonists
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
US6069152A (en) * 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
GB0905641D0 (en) * 2009-04-01 2009-05-13 Serodus As Compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
GB8518658D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Medicaments
EP0278173B1 (en) * 1986-12-17 1993-11-03 Glaxo Group Limited Use of heterocyclic derivatives in the treatment of depressions
IT1231413B (it) * 1987-09-23 1991-12-04 Angeli Inst Spa Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht
ES2061024T3 (es) * 1989-04-21 1994-12-01 Sandoz Ag Uso terapeutico de antagonistas de receptores de 5-ht3.
GB9103862D0 (en) * 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
FR2674853B1 (fr) * 1991-04-03 1995-01-20 Synthelabo Derives de piperidinylguanidine, leur preparation et leur application en therapeutique.
WO1993002677A1 (en) * 1991-08-03 1993-02-18 Smithkline Beecham Plc 5-ht4 receptor antagonists
AU2435092A (en) * 1991-08-20 1993-03-16 Smithkline Beecham Plc 5-ht4 receptor antagonists
US5552398A (en) * 1991-09-12 1996-09-03 Smithkline Beecham P.L.C. Azabicyclic compounds as 5-HT4 receptor antagonists
FI941178L (fi) * 1991-09-12 1994-03-11 Smithkline Beecham Plc 5-HT4-reseptoriantagonisteja
AU2752692A (en) * 1991-10-24 1993-05-21 Smithkline Beecham Plc Imidazopyridines and indolizines as 5-ht4 antagonists
AU3361693A (en) * 1992-01-23 1993-09-01 Smithkline Beecham Plc Use of 5-HT4 receptor antagonists as medicaments for treating migraine
NZ246915A (en) * 1992-02-06 1996-05-28 Smithkline Beecham Plc Benzopyran, benzothiopyran and benzofuran derivatives, preparation and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
EP0641198A1 (en) 1995-03-08
JPH07507290A (ja) 1995-08-10
WO1993024117A3 (en) 1994-04-14
US5763459A (en) 1998-06-09
WO1993024117A2 (en) 1993-12-09
AU4081393A (en) 1993-12-30

Similar Documents

Publication Publication Date Title
MX9304435A (es) Compuesto y composicion farmaceutica para el tratamiento y la profilaxis de la obesidad o para el tratamiento de la diabetes del tipo ii.
BG102668A (en) Application of ppar-alpha and prar-gamma antagonist for the treatment of syndrome x
ES2144119T3 (es) Uso de inhibidores de la ciclooxigenasa no esteroideos para la fabricacion de un medicamento para el tratamiento de una presion intraocular elevada.
ATE91233T1 (de) Antivirale pharmazeutische zusammensetzungen und ihrer verwendung.
MX9300603A (es) Derivados tiaciclicos de piperidinilo.
NO179250C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktiv (+)--(2,3-dimetoksyfenyl)-1-[2-(4-fluorfenyl)etylÅ-4-piperidinmetanol
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
UA41355C2 (uk) Засіб для лікування нейро-сніду
AR008799A1 (es) Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento
AR247984A1 (es) Metodo para la preparacion de una composicion sinergica que tiene actividad antiplaca o antigingivitis
MX9302985A (es) Composicion farmaceutica para el tratamiento y la profilaxis de la ansiedad.
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
DK345889A (da) Anvendelse af 5-ht-3-receptorantagonist
PT684816E (pt) Composicoes antagonistas do receptor da 5-ht2 uteis no tratamento de doencas venosas
EP0992243A4 (en) Prophylactic/remedial agent
MY121604A (en) Combination therapy for hiv infection using the hiv protease inhibitor indinavir and the reverse transcriptase inhibitor 3tc together with azt
DE3875349D1 (de) Glykosaminoglykan zur behandlung von diabetischer mikroangiopathie.
ES2121109T3 (es) Composicion de champu.
ES2181915T3 (es) Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones.
IT8349538A0 (it) Esteri di derivati 3-(3-sostituitoammino-2-idrossi-propossi)-4-sostituito-1,2,5-tiadiazolici utili come agenti bloccanti beta-adrenergici eper il trattamento del glaucoma
AR007059A1 (es) Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto
AR017215A1 (es) Composiciones que contienen generadores de oxido nitrico y uso de dichos generadores para la preparacion de un medicamento util para el tratamiento detrastornos de ojo seco
MX9304878A (es) Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis.
DK0471040T3 (da) Anvendelse af cromakalim/BRL 38227 til behandling af hyperreaktivitet i luftveje
DE69932434D1 (de) Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten